Anticoagulants

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Anticoagulants.php on line 2
Anticoagulants

LE WE PMID CA

Anticoagulants

175

Antikoagulantien

Anticoagulants (Coumarins Phenprocoumon Warfarin)

Anticoagulants

Apixaban

Atherosclerosis (BASKET)

Dabigatran

Endoscopy

Factor IX (Coagulation)

Factor VII (Coagulation)

Heart (Atrial fibrillation)

Heart valve (Artificial)

Osteocalcin

P selectin

Platelets (Therapeutic inhibitors)

Premedication and perioperative medicine

Rivaroxaban

Thrombosis (BASKET)

Tissue factor

1994 1	Hereditary warfarin resistance. [8134868] South Med J 87(3): 407-9 (1994)
2007 2	Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. [17846060] QJM 100(10): 599-607 (2007)
2002 3	Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. [12096150] QJM 95(7): 451-9 (2002)
2006 4	Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. [16505257] Arch Intern Med 166(4): 391-7 (2006)
2005 5	Systematic overview of warfarin and its drug and food interactions. [15911722] Arch Intern Med 165(10): 1095-106 (2005)
1998 6	Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. [9801181] Arch Intern Med 158(19): 2136-40 (1998)
2002 7	Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. [12173205] Br J Anaesth 88(6): 848-63 (2002)
2008 8	Perioperative hemostatic management of patients treated with vitamin K antagonists. [18946305] Anesthesiology 109(5): 918-26 (2008)
2009 9	Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. [20436891] Int J Emerg Med 2(4): 217-25 (2009)
2010 10	Reversal of vitamin K antagonists prior to urgent surgery. [20077167] Can J Anaesth 57(5): 458-67 (2010)
2006 11	Perioperative management of patients receiving vitamin K antagonists. [16766784] Can J Anaesth 53(6 Suppl): S113-22 (2006)
2010 12	Atrial fibrillation and dabigatran: has the time come to use new anticoagulants? [20718760] Cardiovasc Ther 28(5): 295-301 (2010)
2010 13	New antithrombotics for atrial fibrillation. [20645985] Cardiovasc Ther 28(5): 278-86 (2010)
2008 14	Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. [19337550] Vasc Health Risk Manag 4(6): 1373-86 (2008)
2008 15	Future innovations in anti-platelet therapies. [18587441] Br J Pharmacol 154(5): 918-39 (2008)
2006 16	Antiplatelet drugs. [16402110] Br J Pharmacol 147 Suppl 1(): S241-51 (2006)
2005 17	New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. [15711585] Br J Pharmacol 144(8): 1017-28 (2005)
2008 18	[Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. [18278163] Hamostaseologie 28(1-2): 51-61 (2008)
2005 19	New anticoagulants. [16102051] J Thromb Haemost 3(8): 1843-53 (2005)
1997 20	Correction of excessive anticoagulation with low-dose oral vitamin K1. [9182473] Ann Intern Med 126(12): 959-62 (1997)
2008 21	Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. [18309033] Blood 111(10): 4871-9 (2008)
2008 22	Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. [18316627] Blood 111(9): 4471-6 (2008)
2005 23	New anticoagulants. [15191946] Blood 105(2): 453-63 (2005)
2008 24	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). [18574268] Chest 133(6 Suppl): 257S-298S (2008)
2008 25	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). [18574265] Chest 133(6 Suppl): 160S-198S (2008)
1998 26	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. [9822057] Chest 114(5 Suppl): 445S-469S (1998)
2007 27	Conundrums in the combined use of anticoagulants and antiplatelet drugs. [17638939] Circulation 116(3): 305-15 (2007)
2008 28	Vitamin K-dependent proteins, warfarin, and vascular calcification. [18495950] Clin J Am Soc Nephrol 3(5): 1504-10 (2008)
2007 29	Anticoagulants in heart disease: current status and perspectives. [17426080] Eur Heart J 28(7): 880-913 (2007)
2006 30	Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. [16143706] Eur Heart J 27(5): 519-26 (2006)
2008 31	Management of excessive anticoagulant effect due to vitamin K antagonists. [19074094] Hematology Am Soc Hematol Educ Program (): 266-70 (2008)
2008 32	New anticoagulants in children. [19074090] Hematology Am Soc Hematol Educ Program (): 245-50 (2008)
2004 33	Thrombophilia and new anticoagulant drugs. [15561696] Hematology Am Soc Hematol Educ Program -(-): 424-38 (2004)
2001 34	Anticoagulation therapy. [11722992] Hematology Am Soc Hematol Educ Program -(-): 339-57 (2001)
2008 35	Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. [18533078] Mayo Clin Proc 83(6): 628-9 (2008)
1989 36	Long-term anticoagulation. Indications and management. [2686173] West J Med 151(4): 414-29 (1989)
2008 37	'Triple therapy' or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. [18294567] J Am Coll Cardiol 51(8): 826-7 (2008)
2008 38	Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. [18294566] J Am Coll Cardiol 51(8): 818-25 (2008)
2003 39	ABC of antithrombotic therapy: Antithrombotic therapy in special circumstances. II-In children, thrombophilia, and miscellaneous conditions. [12521976] BMJ 326(7380): 93-6 (2003)
2009 40	An algorithm for managing warfarin resistance. [19952297] Cleve Clin J Med 76(12): 724-30 (2009)
2003 41	When patients on warfarin need surgery. [14650471] Cleve Clin J Med 70(11): 973-84 (2003)
2008 42	Should patients on long-term warfarin take aspirin for heart disease? [18383929] Cleve Clin J Med 75(3): 206-8 (2008)
2011 43	Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review. [21628615] Mayo Clin Proc 86(6): 509-21 (2011)
2010 44	New anticoagulants. [20368532] Circulation 121(13): 1523-32 (2010)
2004 45	New anticoagulants for treatment of venous thromboembolism. [15339877] Circulation 110(9 Suppl 1): I19-26 (2004)
2010 46	Combination antithrombotic therapies. [20124137] Circulation 121(4): 569-83 (2010)
2011 47	Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-. [21670542] Circ J 75(8): 1852-9 (2011)
2011 48	Thrombin inhibitor or factor xa inhibitor? -Opening of a New Era of antithrombotic management-. [21673455] Circ J 75(8): 1819-20 (2011)
2011 49	Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. [21666370] Circ J 75(7): 1539-47 (2011)
2010 50	Antithrombotic therapy. ESC guidelines vs JCS guidelines. [21060203] Circ J 74(12): 2542-5 (2010)
2010 51	Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. [20139356] Arterioscler Thromb Vasc Biol 30(3): 382-7 (2010)
2010 52	Rivaroxaban: a new oral factor Xa inhibitor. [20139357] Arterioscler Thromb Vasc Biol 30(3): 376-81 (2010)
2010 53	Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. [20671233] Arterioscler Thromb Vasc Biol 30(10): 1885-9 (2010)
2007 54	Inhibitors of Factor VIIa/tissue factor. [17600222] Arterioscler Thromb Vasc Biol 27(9): 1895-900 (2007)
2009 55	New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? [19491132] Eur Heart J 30(14): 1695-702 (2009)
2007 56	Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations. [17939586] Rev Port Cardiol 26(7-8): 769-88 (2007)
2008 57	The debate concerning oral anticoagulation: whether to suspend oral anticoagulants during dental treatment. [18605071] Rev Port Cardiol 27(4): 531-44 (2008)
2010 58	The new oral anticoagulants. [19880491] Blood 115(1): 15-20 (2010)
2009 59	Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin? [20040270] Discov Med 8(43): 196-203 (2009)
2009 60	Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. [19486503] Crit Care 13(2): 209 (2009)
2010 61	Emergency reversal of warfarin anticoagulation. [21078740] CMAJ 182(18): 2004 (2010)
2007 62	What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? [17669876] Interact Cardiovasc Thorac Surg 6(3): 390-6 (2007)
2010 63	New options with dabigatran etexilate in anticoagulant therapy. [20531953] Vasc Health Risk Manag 6(-): 339-49 (2010)
2010 64	Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. [20167958] Neth J Med 68(2): 68-76 (2010)
2010 65	P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. [19962723] Thromb Res 125(4): e138-42 (2010)
2008 66	Anticoagulants from hematophagous animals. [21082917] Expert Rev Hematol 1(2): 135-9 (2008)
2011 67	Optimal strategies for the management of antiplatelet and anticoagulation medications prior to cardiac device implantation. [21305497] Cardiol J 18(1): 103-9 (2011)
2011 68	Future anticoagulants in interventional cardiology: anti-IXa and anti-Xa agents in percutaneous coronary intervention. [21627469] Future Cardiol 7(3): 281-5 (2011)
2010 69	The management of patients on dual antiplatelet therapy undergoing orthopedic surgery. [21886534] HSS J 6(2): 182-9 (2010)
2011 70	Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. [21547880] Endoscopy 43(5): 445-61 (2011)
2011 71	Laboratory assessment of new anticoagulants. [21288169] Clin Chem Lab Med 49(5): 761-72 (2011)
2010 72	Anticoagulation management. [22550377] Semin Intervent Radiol 27(4): 360-7 (2010)
2010 73	Correction of coagulopathy for percutaneous interventions. [22550375] Semin Intervent Radiol 27(4): 338-47 (2010)
PMC 74	Assessing bleeding risk in patients taking anticoagulants. [23479259] J Thromb Thrombolysis 35(3):312-9 (2013)
PMC 75	Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. [24505487] PLoS One 9(2):e88390 (2014)
PMC 76	New oral anticoagulants: are coagulation units still required? [24491189] Thromb J 12(1):3 (2014)
PMC 77	New oral anticoagulants. [23148053] CMAJ 185(4):E212 (2013)
PMC 78	New Oral Anticoagulants for Atrial Fibrillation: Are They Worth the Risk? [24672216] P T 39(1):54-64 (2014)
PMC 79	Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism. [24749116] Glob Cardiol Sci Pract 2013(4):416-20 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Anticoagulants.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Anticoagulants.php on line 92